Skip to main content
SpringerLink
Log in

Lung cancer – ASCO 2010

  • Short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

Lung cancer remains a disease difficult to treat. Accordingly, results from recently conducted clinical trials are eagerly awaited. Every year, the American Society of Clinical Oncology (ASCO) – Annual Meeting provides the oncological community with a large number of such studies, with some of them potentially changing current treatment standards. The aim of this review is therefore to give a concise overview on this year's Annual Meeting presentations covering the field of lung cancer with an emphasis on randomized phase III trials of immediate clinical importance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Tournoy KG, Dooms CA, et al. A randomized trial comparing endosonography followed by surgical staging versus surgical mediastinal staging alone in non-small cell lung cancer: The ASTER Study. J Clin Oncol, 28: 15s, 2010 (suppl, abstr 7000)

    Google Scholar 

  • Goss GD, Lorimer I, et al. A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinib in completely resected stage IB–IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19. J Clin Oncol, 28: 15s, 2010 (suppl, abstr LBA 7005)

    Article  Google Scholar 

  • Thatcher N, Chang A, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multicenter study (Iressa Survival Evaluation in Lung Cancer). Lancet, 366: 1527–1537, 2005

    Article  PubMed  CAS  Google Scholar 

  • Kelly K, Chansky K, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol, 26: 2450–2456, 2008

    Article  PubMed  CAS  Google Scholar 

  • Azzoli CG, Baker S Jr, et al. American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Clin Oncol, 27: 6251–6266, 2009

    Article  PubMed  CAS  Google Scholar 

  • Quoix EA, Oster J, et al. Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC). J Clin Oncol, 28: 18s, 2010 (suppl, abstr 2)

    Google Scholar 

  • Soda M, Choi YL, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 448: 561–566, 2007

    Article  PubMed  CAS  Google Scholar 

  • Shaw AT, Yeap BY, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbour EML4-ALK. J Clin Oncol, 27: 4232–4235, 2009

    Article  Google Scholar 

  • Bang Y, Kwak EL, et al. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). J Clin Oncol, 28: 18s, 2010 (suppl abstr 3)

    Google Scholar 

  • Temel JS, Greer J, et al. Effect of palliative care (PC) on quality of life (QoL), aggressive care at the end-of-life (EOL), and survival in stage IV NSCLC patients: results of a phase III randomized trial. J Clin Oncol, 28: 15s, 2010 (suppl, abstr 7509)

    Google Scholar 

  • Belani CP, Waterhouse DM, et al. Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol, 28: 15s, 2010 (suppl, abstr 7506)

    Google Scholar 

  • Ciuleanu T, Brodowicz T, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase III study. Lancet, 374: 1432–1440, 2009

    Article  PubMed  CAS  Google Scholar 

  • Cappuzzo F, Ciuleanu T, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicenter, randomised, placebo-controlled phase III study. Lancet Oncol, 11: 521–529, 2010

    Article  PubMed  CAS  Google Scholar 

  • Perol M, Chouaid C, et al. Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. J Clin Oncol, 28: 15s, 2010 (suppl; abstr 7507)

    Google Scholar 

  • Lee S, Rudd R, et al. TOPICAL: Randomised phase III trial of erlotinib compared with placebo in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and unsuitable for first-line chemotherapy. J Clin Oncol, 28: 15s, 2010 (suppl, abstr 7504)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine I/Oncology, District/University Hospital Innsbruck, Innsbruck, Austria

    G. Pall

Authors
  1. G. Pall
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Pall.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pall, G. Lung cancer – ASCO 2010. memo 3, 172–176 (2010). https://doi.org/10.1007/s12254-010-0228-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-010-0228-1

Keywords

Search

Navigation